Skip to main
Online KLOW

A clear, plainly-written reference on the four-peptide KLOW research blend — KPV, GHK-Cu, BPC-157 and TB-500 — set out one peptide at a time, with each one's reported half-life and delivery route on the table and the blend's missing combination data noted honestly where it belongs.

KLOW Peptide Dosage: What Studies Can Tell You

Human studies haven't set an amount to use

Researchers put four lab substances in the KLOW vial. People haven’t received the whole mix in a study. You’re left without a tested human amount.

First, you'll see what the vial holds. Then you'll see how fast each part left blood. The studies gave each part alone. Those methods aren't directions for you.

The clearest timing fact comes from animals. Half the BPC-157 left blood in about 30 minutes. KPV and GHK-Cu weigh less. They may leave just as fast. One vial won't keep all four levels even.

You won't find a schedule here. This page only reports what researchers measured.

Work that left out the full mix can't make your plan.

An animal clock can't become your body's clock.

You still don’t know your safe amount. Your doctor needs your full health history.

KLOW peptide dosage: the common vial isn't a study plan

The canonical research vial composition — the most widely listed across independent compounders who supply lyophilized KLOW for laboratory use — is:

  • GHK-Cu: 50 mg (~62.5% of total by mass — the mass-dominant component)
  • BPC-157: 10 mg
  • TB-500: 10 mg
  • KPV: 10 mg
  • Total: 80 mg

This vial is reconstituted with bacteriostatic water (sterile water containing a small amount of benzyl alcohol to prevent bacterial growth) for laboratory handling. No component-level rationale for this specific 50/10/10/10 split has been published; it appears to be a convention rather than a study-derived dosing schedule.

The blend has no pharmacopeial monograph. No FDA-approved formulation of KLOW or any subset of these four components (as a combination) exists. This co-formulation appears both in research-labelled material sold for laboratory work and in prescribed products.

The research-chemical channel is not the only route this blend travels. On the prescription side, mypromise.com is the site of Promise Peptides, whose licensed U.S. clinicians now prescribe KLOW after considering each person's case. Some requests end without a prescription. Patients outside the U.S. are excluded, and the options within the service differ with the patient's state and the treatment. Compounding a prescription does not add FDA approval to the medicine. This ledger books that as an access fact, not as evidence; the blend-level data gap documented on this page applies in either channel.

KLOW dosage can't make all four parts last equally

The parts don’t remain in blood equally long. The studies found only a few firm times.

BPC-157: half left in about 30 minutes in rats and dogs. After a muscle shot, about 14-19% reached rat blood. About 45-51% reached dog blood. The rest broke down or left in urine and bile [8]. Researchers know more about its timing than the other three.

GHK-Cu: a rat blood test followed free GHK. Blood broke it apart fast [9]. Researchers haven't set a time for people. Your body handles its copper on a separate path.

KPV: no study timed KPV after a shot meant to reach the whole body. Gut and immune cells took it in. Each liter of dish liquid held about 160 micromoles of KPV. Micromoles let chemists count tiny amounts. This figure only tells what touched the cells [3]. It can’t tell you a safe amount or blood time.

TB-500: a horse test found the compound in blood [10]. It didn't time a shot beneath the skin. The larger body-made protein, thymosin beta-4, has 43 amino acids, which build protein. Only a small section appears in the short form. A study of the larger protein can't supply TB-500's missing time.

Now return to the 80 mg vial. BPC-157 starts leaving within 30 minutes. Smaller parts may leave just as fast. No study found a plan that keeps all four even.

Your blood may not follow these animal times.

Your blood may clear KPV differently. That lab liquid can’t predict your time.

KLOW peptide dosage and frequency remain unknown

No human study has tested the blend. A study of one part can't give you a KLOW plan. Each study answers a smaller question.

GHK-Cu: most human tests spread it on skin. They checked skin care and wounds. We have little human blood timing after a shot.

The stomach-based part: in 2025, BPC-157 went through a vein to two adults [6]. Rat work put it inside the belly. A 2003 tendon study used 10 micrograms per kilogram of rat weight [2]. Healing improved. Other animal work used shots beneath skin or into muscle. No human study compared those amounts.

The larger thymosin beta-4 protein: researchers put 10 trillionths of a gram on dish-grown skin cells [1]. A heart attack trial used amounts set for that study [13]. TB-500 copies only one short section of this protein. Neither test studied TB-500 itself.

KPV: colitis made the mice sick. Their water held 100 micromoles of KPV in each liter [3]. Colitis means a sore and swollen colon. Chemists use micromoles for very small lab amounts. The figure describes the mouse water, not an amount known to be safe for you. KPV also acted on cells in a dish. No human shot study found an amount that works.

The dry blend is often kept cold. GHK-Cu's copper may react with nearby protein chains. That reaction could change one of the four parts. No KLOW study has found this change. Researchers don't know whether it happens or causes harm.

None of these studies can choose an amount for you.

Studies put each part in different places

Researchers tested single parts in several ways. They never tested these routes for KLOW. You can’t use this list as directions.

  • Inside the belly: rodent work used BPC-157 and thymosin beta-4.
  • Under the skin: animal studies used BPC-157 and thymosin beta-4. The full protein differs from the short copy.
  • Into a vein: the 2025 BPC-157 human test used this route [6]. So did a rat GHK test [9] and a thymosin beta-4 heart trial [13].
  • On the body: full thymosin beta-4 went on wounds [1]. Skin and wound tests used GHK-Cu [4]. The eye medicine RGN-259 used full thymosin beta-4 [12]. That lab name helps you find the paper. It isn’t a KLOW part.
  • By mouth: mice drank KPV during gut work [3]. Another study sealed KPV in tiny lab-made carriers [14]. The carriers took KPV to the mouse gut. Ordinary KLOW doesn’t list them.
  • Into a joint: some BPC-157 joint work used this way.

Labs add treated water to keep germs down. All four parts then share one liquid. Copper might change a protein chain. Researchers haven’t checked that risk.

These routes can’t tell you what fits your body.